The global Vaccine Contract Manufacturing Market had a valuation of USD 3.6 billion in 2022, and it is anticipated to surge to USD 9.36 billion by 2032, displaying a robust compound annual growth rate (CAGR) of 11.2% over the forecast period. Key drivers behind this remarkable revenue expansion include the increasing prevalence of infectious diseases, a growing demand for innovative vaccines,...